A Clinical Study of MIL95 in Advanced Malignancies.

NCT04651348 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies

Interventions

DRUG: Recombinant Humanized Monoclonal Antibody MIL95

Sponsor

Beijing Mabworks Biotech Co., Ltd.